BioPorto: Jeffrey Haas

Danish diagnostic firm BioPorto has appointed Jeffrey Haas as the company's president and CEO. He will be responsible for the commercial introduction of the firm's US Food and Drug Administration-cleared ProNephro AKI NGAL test that is used to assess the risk of moderate to severe acute kidney injury in pediatric and young adult patients by measuring the biomarker neutrophil gelatinase-associated lipocalin (NGAL). He also will be responsible for leading activities such as increasing awareness about the test, forming partnerships to secure commercial traction for the test, and expanding use of the test to include indications in adult patients. Haas most recently worked for Abbott Laboratories, where he had been vice president of rapid diagnostics and president of the infectious diseases business unit since 2017.